| Literature DB >> 21209447 |
Abstract
Diseases that disproportionately affect developing countries play a large role in stalling economic and social development. Pharmaceutical companies are driving crucial research into new vaccines and medicines; however, although there is an imperative for industry to research new therapies for diseases of the poor, the financial returns are often seen as limited. This is beginning to change. The pharmaceutical industry and the public sector are thinking differently than before about how to improve access to medicines and advance research and development for neglected diseases. The public and private sectors must work together to develop a wide range of innovative tools, partnerships, and approaches.Mesh:
Year: 2011 PMID: 21209447 DOI: 10.1377/hlthaff.2010.0933
Source DB: PubMed Journal: Health Aff (Millwood) ISSN: 0278-2715 Impact factor: 6.301